Wu S-C, Li LS*, Kopp N, Montero J, Chapuy B, Yoda A*, Christie AL, Liu H, Christodoulou A, van Bodegom D*, van der Zwet J*, Layer JV*, Tivey T, Lane AA*, Ryan JA, Ng SY*, DeAngelo DJ, Stone RM, Steensma D, Wadleigh M, Harris M, Mandon E, Ebel N, Andraos R, Romanet V, Dolemeyer A, Sterker D, Zender M, Rodig SJ, Murakami M, Hofmann F, Kuo F, Eck MJ, Silverman LB, Sallan SE, Letai A, Baffert F, Vangrevelinghe E, Radimerski T, Gaul C, Weinstock DM. Activity of the Type II JAK2 inhibitor CHZ868 in B-cell acute lymphoblastic leukemia. Cancer Cell 2015;28:29-41.
http://www.cell.com/cancer-cell/abstract/S1535-6108(15)00215-9
Yeagle P, Green A, Hermine O, et al. Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia. Science Advances 2015;1(8):e1500221.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643770/
Akahane K, Sanda T, Mansour MR, Radimerski T, DeAngelo DJ, Weinstock DM, Look AT. HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia. Leukemia 2015 (online 8/12/15).
http://www.ncbi.nlm.nih.gov/pubmed/26265185
Sujobert, P., Paubelle, E., Grenier, A., Zylbersztejn, F., Lambert, M., Poulain, L., Townsend, E.*, Brusq J-M., Nicodeme, E., Decropqc, D., Nepstad, I., Green A., Hospital, M-A., Jacque, N., Hermine, O., Foretz, M., Viollet, B., Lacombe, D., Mayeux, P., Weinstock, D.M., Moura, I.C., Bouscary, D., Tamburini, J.* Co-activation of AMPK and mTORC1 is synthetically lethal in acute myeloid leukemia. Cell Reports 2015;11:1446-57.
http://www.bloodjournal.org/content/124/21/616?sso-checked=true
Pastore A, Jurinovic V, Kride R, Hoster E, Staiger AM, Szczepanowski M, Pott C, Kopp N, Murakami M*, Horn H, Leich E, Moccia AA, Mottok A, Sunkavalli A, van Hummelen P, Ducar M, Ennishi D, Shulha HP, Hother C, Connors JM, Sehn LH, Dreyling M, Neuberg D, Moller P, Feller AC, Hansmann ML, Stein H, Rosenwald A, Ott G, Klapper W, Unterhalt M, Hiddemann W, Gascoyne RD^, Weinstock DM^, Weigert O*^. Integration of Gene Mutations Improves Risk Prognostication in Patients Receiving First-line Immunochemotherapy for Follicular Lymphoma in Clinical Trial and Population-Based Cohorts. Lancet Oncology (online 8/6/15). ^equal contribution.
http://www.ncbi.nlm.nih.gov/pubmed/26256760
Weinstock DM, Dalla Favera R, Gascoyne RD, Leonard JP, Levy R, Lossos IS, Melnick AM, Nowakowski GS, Press OW, Savage KJ, Shipp MA, Staudt LM. A roadmap for discovery and translation in lymphoma. Blood 2015;125: 2175-7.
http://www.bloodjournal.org/content/125/13/2175?sso-checked=true
LaCasce A, Weinstock DM. Navigating Future Challenges in Lymphoma: A Map for the Road Ahead. The Hematologist 2015 (published on April 14, 2015).
http://www.hematology.org/Thehematologist/Features/4003.aspx
Huang T-C, Civin C, Gojo I, Cutler J, Bharne S, Zhong J, Weinstock D, Tyner JW, Pandey A. Integrated Analysis of CRLF2 Signaling in Acute Lymphoblastic Leukemia Identifies Polo-Like Kinase 1 as a Potential Therapeutic Target. Leuk Lymphoma 2015;56:1524-7.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420723/
Yoda A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y, Weigert O, Kopp N, Wu S-C, Kim SS, Liu H, Tivey T, Christie AL, Elpek KG, Card J, Kritsman K, Gotlib J, Deininger MW, Makishima H, Turley SJ, Javidi-Sharifi N, Maciejewski JP, Jaiswal S, Ebert BL, Rodig SJ, Tyner JW, Marto JA, Weinstock DM^, Lane A^. Mutations in G protein beta subunits promote transformation and kinase inhibitor resistance. Nature Medicine 2015;21:710-5. ^equal contribution
http://www.ncbi.nlm.nih.gov/pubmed/25485910
Schatz JH, Horwitz SM, Teruya-Feldstein J, Lunning M, Viale A, Huberman K, Socci ND, Lailler N, Heguy A, Dolgalev I, Migliacci JC, Pirum N, Palomba ML, Weinstock DM, Wendel H-G. Targeted Mutational Profiling of Peripheral T-Cell Lymphoma Not Otherwise Specified Highlights New Mechanisms in a Heterogeneous Pathogenesis. Leukemia 2015;29:237-41.
http://www.ncbi.nlm.nih.gov/pubmed/25257991
Mansour MR, Reed C, Eisenberg AR, Tseng JC, Twizere JC, Daakour S, Yoda A, Rodig SJ, Tal N, Shochat C, Berezovskaya A, DeAngelo DJ, Sallan SE, Weinstock DM, Izraeli S, Kung AL, Kentsis A, Look AT. Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia. Br J Haematol 2015;168:230-8.
http://www.ncbi.nlm.nih.gov/pubmed/25256574